Orthofix Medical Inc. (NASDAQ:OFIX - Get Free Report) CAO Geoffrey C. Gillespie sold 767 shares of Orthofix Medical stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $17.79, for a total transaction of $13,644.93. Following the transaction, the chief accounting officer now owns 39,323 shares of the company's stock, valued at approximately $699,556.17. The trade was a 1.91 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Orthofix Medical Trading Down 1.5 %
Orthofix Medical stock traded down $0.27 during trading on Friday, hitting $18.20. The company's stock had a trading volume of 102,709 shares, compared to its average volume of 180,222. The stock's fifty day moving average is $18.00 and its 200 day moving average is $17.18. Orthofix Medical Inc. has a 1-year low of $12.08 and a 1-year high of $20.73. The stock has a market capitalization of $695.42 million, a price-to-earnings ratio of -5.81 and a beta of 1.10. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.11 and a current ratio of 2.39.
Orthofix Medical (NASDAQ:OFIX - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The medical device company reported ($0.71) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.57). Orthofix Medical had a negative net margin of 15.18% and a negative return on equity of 21.25%. The company had revenue of $196.61 million for the quarter, compared to analyst estimates of $196.60 million. During the same period in the prior year, the company earned ($0.77) EPS. As a group, equities research analysts predict that Orthofix Medical Inc. will post -2.81 EPS for the current year.
Analysts Set New Price Targets
Several equities analysts have weighed in on OFIX shares. Roth Mkm reissued a "buy" rating and set a $22.00 price target (up previously from $20.00) on shares of Orthofix Medical in a research report on Friday, November 8th. StockNews.com upgraded Orthofix Medical from a "hold" rating to a "buy" rating in a research report on Friday, January 31st. Canaccord Genuity Group started coverage on shares of Orthofix Medical in a report on Wednesday, January 22nd. They issued a "buy" rating and a $24.00 target price on the stock. Finally, Stifel Nicolaus upgraded shares of Orthofix Medical from a "hold" rating to a "buy" rating and lifted their price target for the stock from $18.00 to $24.00 in a report on Friday, November 8th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $23.33.
Check Out Our Latest Stock Report on Orthofix Medical
Hedge Funds Weigh In On Orthofix Medical
Several institutional investors and hedge funds have recently bought and sold shares of OFIX. Inceptionr LLC purchased a new stake in shares of Orthofix Medical during the 4th quarter valued at $279,000. Raymond James Financial Inc. acquired a new position in Orthofix Medical in the fourth quarter valued at $1,003,000. Victory Capital Management Inc. grew its position in Orthofix Medical by 2.9% during the fourth quarter. Victory Capital Management Inc. now owns 66,675 shares of the medical device company's stock valued at $1,164,000 after acquiring an additional 1,868 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Orthofix Medical by 4.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 339,531 shares of the medical device company's stock worth $5,928,000 after acquiring an additional 14,724 shares during the last quarter. Finally, Versor Investments LP purchased a new position in shares of Orthofix Medical in the 4th quarter worth about $499,000. Institutional investors and hedge funds own 89.76% of the company's stock.
About Orthofix Medical
(
Get Free Report)
Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.
Featured Articles
Before you consider Orthofix Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orthofix Medical wasn't on the list.
While Orthofix Medical currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
